Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Sintilimab
The First People's Hospital of Lianyungang
EBV-Positive DLBCL, Nos
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma (NPC)
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Small Cell Lung Cancer Limited Stage
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Ovarian Clear Cell Carcinoma
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Neoplasms
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Sintilimab (approved)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma (HCC)
1 trial -
Sintilimab Combined with Platinum-containing Chemotherapy
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Sintilimab in combination with Multimodality Radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Sintilimab injection plus Inlyta treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Carcinoma, Renal Cell
1 trial -
Sintilimab with Interleukin-2+CAPOX
The First People's Hospital of Lianyungang
Locally Advanced Rectal Adenocarcinoma
1 trial -
Sintilimab,nab-paclitaxel and tegio
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Sirolimus
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hemangioendothelioma
1 trial -
Sirolimus
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Kaposiform Hemangioendothelioma
1 trial -
Sirolimus
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Plastic Bronchitis
1 trial -
Sodium stibogluconate
The First People's Hospital of Lianyungang
Myelodysplastic Syndromes
1 trial -
Sonodynamic therapy(SDT)
The First People's Hospital of Lianyungang
Peripheral Arterial Disease
1 trial -
Spermidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation-induced Xerostomia
1 trial -
Spironolactone 25mg
Hospital Authority, Hong Kong
Atrial Fibrillation
1 trial -
Spray of spirulina derivatives
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation-induced Oral Mucositis
1 trial -
Stem Cell Educator
The First People's Hospital of Lianyungang
Alopecia Areata
1 trial -
Stivarga 40 mg film-coated tablets
Ningbo Cancer Hospital
Bone sarcoma
1 trial -
Streptococcus salivarius K12
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources